Radical prostatectomy for high-risk prostate cancer

World Journal of Urology

Volumn 26, Issue 3, 2008, Pages 219-224

  Yossepowitch, Ofer ^b   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Disease free survival; Metastasis; Prostatectomy; Prostatic neoplasms; Risk stratification

Indexed keywords

ARTICLE; BIOPSY; CANCER STAGING; HUMAN; MALE; METHODOLOGY; MORBIDITY; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; RISK FACTOR; SURVIVAL RATE;

BIOPSY; HUMANS; MALE; MORBIDITY; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 44649141981     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0247-2     Document Type: Article

References (35)

1. Kane CJ, Presti JC Jr, Amling CL, Aronson WJ, Terris MK, Freedland SJ (2007) Changing nature of high risk patients undergoing radical prostatectomy. J Urol 177:113-117
2. Meng MV, Elkin EP, Latini DM, Duchane J, Carroll PR (2005) Treatment of patients with high risk localized prostate cancer: Results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol 173:1557-1561
3. Denberg TD, Glode LM, Steiner JF, Crawford ED, Hoffman RM (2006) Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int 98:335-340
4. Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 23:8146-8151
5. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H (2005) Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95:751-756
6. Gerber GS, Thisted RA, Chodak GW, Schroder FH, Frohmuller HG, Scardino PT, Paulson DF, Middleton AW Jr, Rukstalis DB, Smith JA Jr, Ohori M, Theiss M, Schellhammer PF (1997) Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis. Eur Urol 32:385-390
7. Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA (2001) Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57:281-285
8. Dreicer R, Magi-Galluzzi C, Zhou M, Rothaermel J, Reuther A, Ulchaker J, Zippe C, Fergany A, Klein EA (2004) Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63:1138-1142
9. Donohue JF, Bianco FJ Jr, Kuroiwa K, Vickers AJ, Wheeler TM, Scardino PT, Reuter VA, Eastham JA (2006) Poorly differentiated prostate cancer treated with radical prostatectomy: Long-term outcome and incidence of pathological downgrading. J Urol 176:991-995
10. Lau WK, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2002) Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol 167:117-122
11. Grossfeld GD, Chang JJ, Broering JM, Li YP, Lubeck DP, Flanders SC, Carroll PR (2001) Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: Results from the cancer of the prostate strategic urologic research endeavor database. J Urol 165:851-856
12. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: Critical analysis of risk assessment methods. J Urol 178:493-499; discussion 499
13. Eastham JA, Riedel E, Scardino PT, Shike M, Fleisher M, Schatzkin A, Lanza E, Latkany L, Begg CB (2003) Variation of serum prostate-specific antigen levels: An evaluation of year-to-year fluctuations. Jama 289:2695-2700
14. D'Amico AV, Chen MH, Roehl KA, Catalona WJ (2004) Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135
15. D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW (2007) Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110:56-61
16. Bianco FJ Jr, Kattan MW, Scardino PT (2004) PSA velocity and prostate cancer. N Engl J Med 351:1800-1802; author reply 1800-1802
17. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama 280:969-974
18. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177:2106-2131
19. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2006) Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist. J Natl Cancer Inst 98:839-845
20. Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV (2006) Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 107:2597-2603
21. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama 294:433-439
22. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Kattan MW (2005) Pretreatment nomogram predicting the long-term risk of metastatic progression of prostate cancer after radical prostatectomy. J Clin Oncol 23:4545
23. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. Jama 293:2095-2101
24. Berglund RK, Jones JS, Ulchaker JC, Fergany A, Gill I, Kaouk J, Klein EA (2006) Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: A prospective analysis. Urology 67:1253-1256
25. Yossepowitch O, Eggener SE, Serio AM, Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA (2007) Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol [Epub ahead of print]; doi:10.1016/j.eururo.2007.10.008
26. Loeb S, Smith ND, Roehl KA, Catalona WJ (2007) Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69:1170-1175
27. Kundu SD, Roehl KA, Eggener SE, Antenor JA, Han M, Catalona WJ (2004) Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 172:2227-2231
28. Gontero P, Marchioro G, Pisani R, Zaramella S, Sogni F, Kocjancic E, Mondaini N, Bonvini D, Tizzani A, Frea B (2007) Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 51:922-929; discussion 929-930
29. Bianco FJ Jr, Scardino PT, Eastham JA (2005) Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 66:83-94
30. Saranchuk JW, Kattan MW, Elkin E, Touijer AK, Scardino PT, Eastham JA (2005) Achieving optimal outcomes after radical prostatectomy. J Clin Oncol 23:4146-4151
31. Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, Gonen M, Reuter V, Scardino PT (2003) Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 170:2292-2295
32. Bianco FJ Jr, Riedel ER, Begg CB, Kattan MW, Scardino PT (2005) Variations among high volume surgeons in the rate of complications after radical prostatectomy: Further evidence that technique matters. J Urol 173:2099-2103
33. Walz J, Graefen M, Huland H (2007) Basic principles of anatomy for optimal surgical treatment of prostate cancer. World J Urol 25:31-38
34. Ogura K, Maekawa S, Okubo K, Aoki Y, Okada T, Oda K, Watanabe Y, Tsukayama C, Arai Y (2001) Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: Correlation with histopathologic results. Urology 57:721-726
35. Tsuzuki T, Hernandez DJ, Aydin H, Trock B, Walsh PC, Epstein JI (2005) Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. J Urol 173:450-453